The smart solution for preclinical development

Depend on Noble Life Sciences as your partner for high-quality, detail-oriented R&D.

Contact Us Today »

Noble Life Sciences Partners with BioFactura to Offer Cell Line Development and Preclinical Protein Production Services

Posted: July 25th 2012

Noble Life Sciences Partners with BioFactura to Offer Cell Line Development and Preclinical Protein Production Services

Gaithersburg, MD (July 25, 2012) – Noble Life Sciences, Inc., a preclinical drug development contract research organization (CRO), today announced a partnership with BioFactura, Inc. (Rockville, MD), a developer and provider of proprietary technologies and services for production of biological.

The collaboration expands Noble’s CRO services to include the development and production of monoclonal antibody and other protein-based drugs. Through the partnership, Noble becomes the exclusive commercial contract services provider of BioFactura’s technologies and capabilities.

BioFactura’s capabilities enable rapid, scalable, high potency production of protein drug candidates in mammalian and microbial systems, from development of expression vectors and cell lines to growth medium optimization, protein purification, and process scale-up. BioFactura’s StableFast™ biomanufacturing platform is a unique, patented system for developing stable mammalian NS0 cell lines that can generate over one gram of protein in eight weeks.

“This relationship allows Noble to offer end-to-end preclinical biopharmaceutical development services – from cell line development to protein production, in vitro screening, in vivo efficacy and pharmacodynamics testing and biomarker development” said Alain Cappeluti, Noble Life Sciences President.

“We are looking forward to working with Noble to provide drug developers wider access to our unique capabilities,” said Darryl Sampey, BioFactura’s President and CEO. “This partnership creates an excellent synergy between Noble’s experienced scientific drug development team and BioFactura’s protein bioprocessing expertise.”

About Noble Life Sciences

Noble Life Sciences provides in vitro and in vivo preclinical development services including experimental design and testing, disease models, selection and validation of biomarkers for personalized medicine, and vivarium services. With deep expertise in preclinical drug development, the company offers access to their top scientists who work collaboratively with researchers in pharmaceutical, biotechnology, and diagnostic companies as well as those in academic and government institutions to expedite preclinical and clinical development. For more information about Noble Life Sciences, visit

About BioFactura

BioFactura offers companies developing biological drugs, such as monoclonal antibodies, shorter time-to-market, reduced costs, and high potency, high fidelity candidates through the application of its proprietary StableFastTM Biomanufacturing Platform. BioFactura’s team has extensive biopharmaceutical industry experience in bioprocess development, scale-up, and cGMP manufacturing. The Company’s service capabilities range from mammalian and microbial cell line generation to upstream and downstream bioprocesses and analytical assay development. For more information about BioFactura, visit

« Back to News